Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 21, 2009, Pages 6148-6156

  Parlow, John J ^a   Burney, Mary W ^a   Case, Brenda L ^a   Girard, Thomas J ^a   Hall, Kerri A ^a   Hiebsch, Ronald R ^a   Huff, Rita M ^a   Lachance, Rhonda M ^a   Mischke, Deborah A ^a   Rapp, Stephen R ^a   Woerndle, Rhonda S ^a   Ennis, Michael D ^a  

^a PFIZER INC   (United States)

Author keywords

Antiplatelet; Antithrombotic; Cardiovascular disease; GPCR antagonist; P2Y12 antagonist; P2Y12 receptor

Indexed keywords

GLUTAMIC ACID DERIVATIVE; NITROGEN; OXYGEN; PIPERAZINE DERIVATIVE; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIMIDINE DERIVATIVE; SULFUR; TICAGRELOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; IC 50; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; FIBRINOLYTIC AGENTS; GLUTAMIC ACID; HUMANS; MALE; PIPERIDINES; PLATELET AGGREGATION; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71749090236     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.017     Document Type: Article

References (35)

1. Horiuchi H. Ann. Med. 38 (2006) 162
2. Gachet C. Thromb. Haemostasis 86 (2001) 222
3. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., Yang R.B., Nurden P., Nurden A., Julius D., and Conley P.B. Nature 409 (2001) 202
4. Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., Pascal M., and Herbert J.M. Thromb. Haemostasis 84 (2000) 891
5. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Circulation 107 (2003) 2908
6. (A) For reviews see:. Angiolillo D.J. Am. J. Cardiovasc. Drugs 7 (2007) 423
7. Cattaneo M. Ex. Rev. Cardiovasc. Ther. 5 (2007) 45
8. Storey R.F. Curr. Pharm. Design 12 (2006) 1255
9. Boeynaems J.M., van Giezen H., Savi P., and Herbert J.M. Curr. Opin. Invest. Drugs 6 (2005) 275
10. (B) For papers see:. Bryant J., Post J.M., Alexander S., Wang Y.X., Kent L., Schirm S., Tseng J.L., Subramanyam B., Buckman B., Islam I., Yuan S., Sullivan M.E., Snider M., and Morser J. Thromb. Res. 122 (2008) 523
11. Post J.M., Alexander S., Wang Y.X., Vincelette J., Vergona R., Kent L., Bryant J., Sullivan M.E., Dole W.P., Morser J., and Subramanyam B. Thromb. Res. 122 (2008) 533
12. Wang Y.X., Vincelette J., da Cunha V., Martin-McNulty B., Mallari C., Fitch R.M., Alexander S., Islam I., Buckman B.O., Yuan S., Post J.M., Subramanyam B., Vergona R., Sullivan M.E., Dole W.P., Morser J., and Bryant J. Thromb. Haemostasis 97 (2007) 847
13. Springthorpe B., Bailey A., Barton P., Birkinshaw T.N., Bonnert R.V., Brown R.C., Chapman D., Dixon J., Guile S.D., Humphries R.G., Hunt S.F., Ince F., Ingall A.H., Kirk I.P., Leeson P.D., Leff P., Lewis R.J., Martin B.P., McGinnity D.F., Mortimore M.P., Paine S.W., Pairaudeau G., Patel A., Rigby A.J., Riley R.J., Teobald B.J., Tomlinson W., Webborn P.J.H., and Willis P.A. Bioorg. Med. Chem. Lett. 17 (2007) 6013
14. Husted S., Emanuelsson H., Heptinstall S., Sandset P.M., Wickens M., and Peters G. Eur. Heart J. 27 (2006) 1038
15. Van Giezen J.J.J., and Humphries R.G. Sem. Thromb. Hemost. 31 (2005) 195
16. De Marco A., de Candia M., Carotti A., Cellamare S., De Candia E., and Altomare C. Eur. J. Pharm. Sci. 22 (2004) 153
17. Yang J., Hua W., Wang F., Wang Z., and Wang X. Bioorg. Med. Chem. 12 (2004) 6547
18. Bryant, J. A.; Buckman, B. O.; Islam, I.; Mohan, R.; Morrissey, M. M.; Wei, G. P.; Xu, W.; Yuang, S. WO 052366, 2004
19. De Candia M., Summo L., Carrieri A., Altomare C., Nardecchia A., Cellamare S., and Carotti A. Bioorg. Med. Chem. 11 (2003) 1439
20. Yang S.W., Buivich A., Chan T.M., Smith M., Lachowicz J., Pomponi S.A., Wright A.E., Mierzwa R., Patel M., Gullo V., and Chu M. Bioorg. Med. Chem. Lett. 13 (2003) 1791
21. Xu B., Stephens A., Kirschenheuter G., Greslin A.F., Cheng X., Sennelo J., Cattaneo M., Zighetti M.L., Chen A., Kim S.A., Kim H.S., Bischofberger N., Cook G., and Jacobson K.A. J. Med. Chem. 45 (2002) 5694
22. Bryant, J. A.; Buckman, B. O.; Islam, I.; Mohan, R.; Morrissey, M. M.; Wei, G. P.; Xu, W.; Yuang, S. WO 098856, 2002
23. Parlow J.J., Case B.L., Girard T.J., Hall K.A., Hiebsch R.R., Huff R.M., Lachance R.M., Mischke D.A., Rapp S.R., Woerndle R.S., and Ennis M.D. Bioorg. Med. Chem. Lett. 19 (2009) 4657
24. Caroff, E.; Hilpert, K.; Meyer, E. WO 050301, 2008
25. Caroff, E.; Hilpert, K.; Meyer, E. WO 044217, 2008
26. Caroff, E.; Fretz, H.; Hilpert, K.; Houille, O.; Hubler, F.; Meyer, E. WO 114774, 2006.
27. Honma Y., Sekine Y., Hashiyama T., Takeda M., Ono Y., and Tsuzurahara K. Chem. Pharm. Bull. 30 (1982) 4314
28. Shaw G., and Sugowdz G. J. Chem. Soc. (1954) 665
29. 33P-MeSADP, and serial dilutions of test compounds, vehicle or 300 nM 2-MeSADP for the definition of non-specific binding. Dry compounds were prepared as 10 mM DMSO stocks and were diluted in seven-point, threefold dilution series in assay buffer with 0.02% BSA. Each concentration was run in triplicate beginning at 10 mM, final concentration in the assay. Binding reactions were incubated at room temperature for 1 h and stopped by dilution and transfer/aspiration of the mixture onto GF/B UniFilter 96 Well Plates (Perkin-Elmer), and washed 3× with ice-cold 50 mM Tris, pH 7.4. The filter plates were counted on a Top Count (Perkin-Elmer) and data were analyzed using GraphPad Prism using a single site binding equation.
30. 50 data was normalized against these two standards to minimize donor-to-donor variability.
31. Ennis, M. D.; Kortum, S. W.; Rahman, H.; Schweitzer, B. A.; Tenbrink, R. E. WO 2006079916, 2006.
32. 50 value of the functional PRP assay was attributed to protein binding. These compounds showed significantly reduced binding affinity when 0.4% human serum albumin was added to the binding assay.
33. Compounds were incubated in human liver and rat liver microsomes for 30 min and the percent remaining was measured. These compounds can be categorized as having good metabolic stability with percent remaining values of >80%.
34. Compounds were examined at a single concentration (3 μM) and conducted in duplicate using a minimum of one positive control inhibitor per CYP-specific assay which included CYP1A2, CYP2C9, CYP2D6, and CYP3A4. Incubation time for the assays were 30 min at 37 °C and end-point measurements were used to assess the degree of inhibition. These compounds can be categorized as weak inhibitors with percent inhibition values of <25%.
35. Compounds were examined at a single concentration (10 μM) in a 384 well fluorescence polarization assay using Cy3B tagged N-desmethyl dofetilide to competitively bind to HEK-hERG membrane homogenates. Incubation time for the assay was 120 min and end-point measurements were used to assess the degree of inhibition. These compounds can be categorized as weak inhibitors with percent inhibition values of <25%.